首都食品与医药
首都食品與醫藥
수도식품여의약
Capital Medicine
2015年
18期
38-39
,共2页
骨髓增生异常综合征%免疫表达%地西他宾
骨髓增生異常綜閤徵%免疫錶達%地西他賓
골수증생이상종합정%면역표체%지서타빈
myelodysplastic syndrome%immune expression%decitabine
目的:探讨地西他滨与三氧化二砷治疗骨髓增生异常综合征的疗效观察。方法骨髓增生异常综合征的患者40例,对其随机分为两组,即为对照组和实验组,单纯使用亚砷酸注射液进行治疗的为对照组,使用低剂量地西他宾与三氧化二砷进行治疗的一组为实验组,观察使用地西他宾与三氧化二砷治疗后的临床效果。结果实验组经用药后的1、3、7天的血管内皮生长因子的评分明显低于对照组;实验组无病存活期和总体存活期明显高于对照组的无病存活期、总体存活期,统计学上有意义(P<0.05)。结论对骨髓增生异常综合征的治疗使用地西他宾与三氧化二砷疗效较佳,降低医药费用,缩短病程,患者在治疗过程中无不适,特别为高危骨髓增生异常的患者的治疗较为适应。
目的:探討地西他濱與三氧化二砷治療骨髓增生異常綜閤徵的療效觀察。方法骨髓增生異常綜閤徵的患者40例,對其隨機分為兩組,即為對照組和實驗組,單純使用亞砷痠註射液進行治療的為對照組,使用低劑量地西他賓與三氧化二砷進行治療的一組為實驗組,觀察使用地西他賓與三氧化二砷治療後的臨床效果。結果實驗組經用藥後的1、3、7天的血管內皮生長因子的評分明顯低于對照組;實驗組無病存活期和總體存活期明顯高于對照組的無病存活期、總體存活期,統計學上有意義(P<0.05)。結論對骨髓增生異常綜閤徵的治療使用地西他賓與三氧化二砷療效較佳,降低醫藥費用,縮短病程,患者在治療過程中無不適,特彆為高危骨髓增生異常的患者的治療較為適應。
목적:탐토지서타빈여삼양화이신치료골수증생이상종합정적료효관찰。방법골수증생이상종합정적환자40례,대기수궤분위량조,즉위대조조화실험조,단순사용아신산주사액진행치료적위대조조,사용저제량지서타빈여삼양화이신진행치료적일조위실험조,관찰사용지서타빈여삼양화이신치료후적림상효과。결과실험조경용약후적1、3、7천적혈관내피생장인자적평분명현저우대조조;실험조무병존활기화총체존활기명현고우대조조적무병존활기、총체존활기,통계학상유의의(P<0.05)。결론대골수증생이상종합정적치료사용지서타빈여삼양화이신료효교가,강저의약비용,축단병정,환자재치료과정중무불괄,특별위고위골수증생이상적환자적치료교위괄응。
Objective To investigate the expression of myelodysplastic syndrome immune to his influence on the West Penn treatment.Methods 40 cases patients with myelodysplastic syndrome, and its randomly divided into two groups, namely the control and experimental groups, the use of arsenic trioxide treatment for the control group, the use of the low-dose decitabine arsenic trioxide as experimental group, and then want to express myeloproliferative syndrome clinical results using immune to West after his treatment at Penn to be seen.Results The experimental <br> group 1,3,7 days after administration of vascular endothelial growth factor scores were significantly lower than the control group; experimental group of disease-free survival and overall survival was significantly higher than the control group disease-free survival, overall survival period, statistically significant (P<0.05).Conclusion The efficacy of his treatment using the West Penn's comprehensive immune myelodysplastic better expression, reduce medical costs, shorten the course, the patient no discomfort during treatment, especially for the treatment of patients with high-risk myelodysplastic more unusual adaptation.